海通国际：信达生物(01801)与武田制药达成114亿美元交易合作商业化值得期待

智通财经网10-23

智通财经APP获悉，海通国际发布研报称，信达生物(01801)与武田制药达成全球战略合作(链接)，包括两款后期在研疗法IBI363(PD-1/IL-2α-bias)、IBI343(CLDN18.2 ADC)，以及一款早期研发项目IBI3001(EGFR/B7H3 ADC)的选择权。信达生物将获得12亿美元的首付款(其中包含1亿美元的战略股权投资)，合计最高可达102亿美元的潜在里程碑付款，以及...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2577374117?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20251023/20251023152608_45289.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2025-10-23 17:00","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2577374117","market":"us","top_or_hot":-1,"title":"海通国际：信达生物(01801)与武田制药达成114亿美元交易 合作商业化值得期待","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，海通国际发布研报称，信达生物(01801)与武田制药达成全球战略合作(链接)，包括两款后期在研疗法IBI363(PD-1/IL-2α-bias)、IBI343(CLDN18.2  ADC)，以及一款早期研发项目IBI3001(EGFR/B7H3  ADC)的选择权。信达生物将获得12亿美元的首付款(其中包含1亿美元的战略股权投资)，合计最高可达102亿美元的潜在里程碑付款，以及...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1358731.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海通国际：信达生物(01801)与武田制药达成114亿美元交易 合作商业化值得期待</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海通国际：信达生物(01801)与武田制药达成114亿美元交易 合作商业化值得期待\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-23 17:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1358731.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，海通国际发布研报称，信达生物(01801)与武田制药达成全球战略合作(链接)，包括两款后期在研疗法IBI363(PD-1/IL-2α-bias)、IBI343(CLDN18.2  ADC)，以及一款早期研发项目IBI3001(EGFR/B7H3  ADC)的选择权。信达生物将获得12亿美元的首付款(其中包含1亿美元的战略股权投资)，合计最高可达102亿美元的潜在里程碑付款，以及...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1358731.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828557.USD","symbol_name":"AZ EQUITY CHINA \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1358731.html","article_id":"2577374117","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20251023/20251023152608_45289.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577374117","pubTimestamp":1761210001,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"该行看好IBI363作为下一代肿瘤基石疗法的潜力，其有望持续拓展治疗边界，未来市场空间巨大。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","01801":"信达生物","BK1583":"高瓴概念","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK4007":"制药","BK1589":"北水核心资产","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","TAK":"武田制药"},"translate_title":"Haitong International: Innovent Biologics (01801) and Takeda Pharmaceutical reached a US $11.4 billion transaction, and the commercialization of cooperation is worth looking forward to","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1.5,"01801":1.5},"content_text":"智通财经APP获悉，海通国际发布研报称，信达生物(01801)与武田制药达成全球战略合作(链接)，包括两款后期在研疗法IBI363(PD-1/IL-2α-bias)、IBI343(CLDN18.2  ADC)，以及一款早期研发项目IBI3001(EGFR/B7H3  ADC)的选择权。信达生物将获得12亿美元的首付款(其中包含1亿美元的战略股权投资)，合计最高可达102亿美元的潜在里程碑付款，以及潜在销售分成(除IBI363在美国市场双方将采用利润损失共担模式)。该行看好IBI363作为下一代肿瘤基石疗法的潜力，其有望持续拓展治疗边界，未来市场空间巨大。全球IO响应人群约150万，对应500亿美元热肿瘤市场。若拓展至IO耐药人群(约100万)及冷肿瘤人群(约140万)，其市场空间有望扩大至1500–2000亿美元。作为“升级版“PD-1，IBI363通过其双重激活与α  bias减毒机制，有望突破IL2剂量瓶颈。IBI363目前已积累的超过1200例患者的临床数据，信达生物和武田制药计划将率先推进IBI363于非小细胞肺癌(NSCLC)与结直肠癌(CRC)的全球开发，包括拓展至一线NSCLC和一线CRC适应症;此外，双方近期计划拓展IBI363至更多适应症的临床开发。目前IBI363的首个全球3期临床研究(MarsLight-11)的IND获FDA批准，用于治疗IO耐药的鳞状非小细胞肺癌(sqNSCLC)患者。该研究将评估IBI3633mg/kg剂量单药治疗相较多西他赛，在治疗经铂类化疗及抗PD-1/PD-L1免疫治疗进展后的sqNSCLC患者中的疗效和安全性。该研究的主要终点为OS。共同开发与商业化的模式，将助力信达生物积累搭建全球临床与商业化团队的经验。该行认为本次合作将充分利用信达生物在中国国内的开发效率和武田制药的国际化开发能力。武田制药每年研发投入约50亿美金，拥有4500人的临床团队，在肿瘤、免疫治疗领域具备丰富的临床、商业化经验。本次合作将有助于信达生物拓展全球布局，逐步在国际核心市场建立研发与商业化平台能力，并最大化可持续发展的长期价值。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577374117","isCrawlerRequest":true}

海通国际：信达生物(01801)与武田制药达成114亿美元交易 合作商业化值得期待

精彩评论

海通国际：信达生物(01801)与武田制药达成114亿美元交易合作商业化值得期待